報價延遲最少15分鐘:2026/06/22 05:20 EDT
盤前時段
|
||||
|
21.42 
|
|
|
常規時段 (已結束)
|
|
|
|
|
||||||||||||
|
|
|
|
|
22
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-2.62/--
|
|
企業價值
--
|
| 資產負債 |
|
每股賬面淨值
不適用
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
--
|
|
每股收益
--
|
|
同行比較
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
同行比較之報價最少15分鐘延遲 (夜盤時段除外)
|
業務概覽
|
|||
| Kardigan Inc is a clinical-stage therapeutics company focused on developing medicines for cardiovascular diseases. Its activities include the research and development of targeted therapies for cardiovascular conditions for which no approved treatments currently exist. The company's clinical-stage programs include Danicamtiv, Ataciguat, and Tonlamarsen, which are being developed for cardiovascular disease indications. The company operates and manages its business as a singleoperating and reportable segment, focused on the discovery and development of novel therapeutic products to treat cardiovascular disease. |
